JP2002531135A - クラミジア感染に対する２段階免疫感作法 - Google Patents

クラミジア感染に対する２段階免疫感作法

Info

Publication number
JP2002531135A
JP2002531135A JP2000586931A JP2000586931A JP2002531135A JP 2002531135 A JP2002531135 A JP 2002531135A JP 2000586931 A JP2000586931 A JP 2000586931A JP 2000586931 A JP2000586931 A JP 2000586931A JP 2002531135 A JP2002531135 A JP 2002531135A
Authority
JP
Japan
Prior art keywords
chlamydia
strain
protein
attenuated
momp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531135A5 (enExample
Inventor
マーディン、アンドリュー、ディー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Sanofi Pasteur Ltd
Original Assignee
University of Manitoba
Aventis Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba, Aventis Pasteur Ltd filed Critical University of Manitoba
Publication of JP2002531135A publication Critical patent/JP2002531135A/ja
Publication of JP2002531135A5 publication Critical patent/JP2002531135A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000586931A 1998-12-04 1999-12-02 クラミジア感染に対する２段階免疫感作法 Pending JP2002531135A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11085598P 1998-12-04 1998-12-04
US60/110,855 1998-12-04
PCT/CA1999/001151 WO2000034498A1 (en) 1998-12-04 1999-12-02 Two-step immunization procedure against chlamydia infection

Publications (2)

Publication Number Publication Date
JP2002531135A true JP2002531135A (ja) 2002-09-24
JP2002531135A5 JP2002531135A5 (enExample) 2007-02-08

Family

ID=22335290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586931A Pending JP2002531135A (ja) 1998-12-04 1999-12-02 クラミジア感染に対する２段階免疫感作法

Country Status (10)

Country Link
US (6) US6676949B2 (enExample)
EP (1) EP1169465B1 (enExample)
JP (1) JP2002531135A (enExample)
AT (1) ATE318924T1 (enExample)
AU (1) AU772356B2 (enExample)
CA (1) CA2366462C (enExample)
DE (1) DE69930147T2 (enExample)
MX (1) MXPA01005615A (enExample)
NZ (1) NZ512730A (enExample)
WO (1) WO2000034498A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012139221A (ja) * 2002-11-07 2012-07-26 Synergy America Inc 肺炎球菌感染を治療または予防するための組成物および方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01005615A (es) * 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
EP1240331B1 (en) * 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20040170636A1 (en) * 2001-03-29 2004-09-02 Greg Matlashewski Leishmania vaccines
US20070060904A1 (en) * 2005-03-14 2007-03-15 Becton, Dickinson And Company Filling system and method for syringes with short needles
EP2907523B1 (en) 2009-01-29 2018-03-28 British Columbia Cancer Agency Branch Compositions comprising chlamydia antigens
WO2014113541A1 (en) * 2013-01-16 2014-07-24 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002179A1 (en) * 1996-07-12 1998-01-22 Connaught Laboratories Limited Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
WO1998002546A2 (en) * 1996-07-12 1998-01-22 University Of Manitoba Dna immunization against chlamydia infection
WO1998010789A1 (en) * 1996-09-12 1998-03-19 Connaught Laboratories Limited Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) * 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5821055A (en) 1985-01-14 1998-10-13 Washington Research Foundation Chlamydia major outer membrane protein
DE3650571T2 (de) 1985-01-14 1997-02-27 Chiron Corp Hauptprotein der Aussenmembran von Chlamydia
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
DE69027313T2 (de) * 1989-03-31 1997-01-23 Univ Washington Impfstoffe enthaltende avirulente phop-type mikroorganismen
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
TW201794B (enExample) * 1991-05-03 1993-03-11 American Cyanamid Co
US5840297A (en) * 1993-03-19 1998-11-24 Johns Hopkins University Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process
NZ276874A (en) * 1993-11-03 1997-11-24 Pfizer Vaccine for treating chlamydia comprising a major outer membrane protein and lipopolysaccharide preparation from a chlamydia organism
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
GB9516293D0 (en) * 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
US6001372A (en) * 1995-08-25 1999-12-14 Wisconsin Alumni Research Foundation Antigenic peptides of Chlamydia trachomatis
AU3210997A (en) * 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US6235290B1 (en) * 1997-07-11 2001-05-22 University Of Manitoba DNA immunization against chlaymdia infection
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US6696421B2 (en) * 1996-07-12 2004-02-24 University Of Manitoba DNA immunization against chlamydia infection
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
ES2253789T3 (es) * 1997-04-18 2006-06-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Cepa de salmonella atenuada usada como vehiculo para inmunizacion oral.
US5935816A (en) * 1997-07-23 1999-08-10 Smithkline Beecham Corporation Chlamydia trachomatis lysS polynucleotides
WO1999010005A1 (en) * 1997-08-28 1999-03-04 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Vaccines for chlamydia psittaci infections
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
ATE480625T1 (de) * 1997-11-21 2010-09-15 Merck Serono Biodevelopment Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
US20020064517A1 (en) * 1998-04-30 2002-05-30 Stewart A. Cederholm-Williams Fibrin sealant as a transfection/transformation vehicle for gene therapy
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
US6660275B2 (en) * 1998-07-27 2003-12-09 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU4793499A (en) * 1998-07-27 2000-02-21 Aventis Pasteur Limited (chlamydia) antigens and corresponding dna fragments and uses thereof
US20030147924A1 (en) * 1998-07-27 2003-08-07 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding dna fragments and uses thereof
US6693087B1 (en) * 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) * 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5366099A (en) * 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6649370B1 (en) * 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6403101B1 (en) * 1998-10-28 2002-06-11 Connaught Laboratories Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6872814B2 (en) * 1998-10-29 2005-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) * 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
AU3790900A (en) * 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
MXPA01005615A (es) * 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
US6448234B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CA2354431A1 (en) * 1998-12-23 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US7297341B1 (en) * 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) * 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6808713B1 (en) * 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP2172214A3 (en) * 1999-03-12 2011-03-16 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2000066739A2 (en) * 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6191259B1 (en) * 1999-05-19 2001-02-20 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US6225443B1 (en) * 1999-05-19 2001-05-01 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
CA2385325C (en) * 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) * 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001036455A2 (en) * 1999-11-12 2001-05-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001046226A2 (en) * 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1240331B1 (en) * 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU2138501A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) * 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) * 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100706A1 (en) * 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020082402A1 (en) * 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20040254130A1 (en) * 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
JP3653219B2 (ja) * 2000-10-30 2005-05-25 シャープ株式会社 印刷装置およびそれを用いた通信装置または情報処理装置
JP2008521434A (ja) * 2004-11-30 2008-06-26 エーラス グローバル ティービー ワクチン ファウンデーション 組換え二重鎖ＲＮＡヌクレオカプシド類（ｒｄｓＲＮｓ）の生成および産生に有用なバクテリア・パッケージング株およびそれらの利用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002179A1 (en) * 1996-07-12 1998-01-22 Connaught Laboratories Limited Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
WO1998002546A2 (en) * 1996-07-12 1998-01-22 University Of Manitoba Dna immunization against chlamydia infection
WO1998010789A1 (en) * 1996-09-12 1998-03-19 Connaught Laboratories Limited Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012139221A (ja) * 2002-11-07 2012-07-26 Synergy America Inc 肺炎球菌感染を治療または予防するための組成物および方法

Also Published As

Publication number Publication date
MXPA01005615A (es) 2004-08-19
US20090215151A1 (en) 2009-08-27
US20020168382A1 (en) 2002-11-14
US20040131630A1 (en) 2004-07-08
CA2366462A1 (en) 2000-06-15
WO2000034498A1 (en) 2000-06-15
US20080182320A1 (en) 2008-07-31
AU772356B2 (en) 2004-04-22
US20040126382A1 (en) 2004-07-01
US7026300B2 (en) 2006-04-11
EP1169465B1 (en) 2006-03-01
US6676949B2 (en) 2004-01-13
ATE318924T1 (de) 2006-03-15
AU1540700A (en) 2000-06-26
NZ512730A (en) 2003-12-19
DE69930147D1 (de) 2006-04-27
CA2366462C (en) 2011-08-09
US20080095804A1 (en) 2008-04-24
EP1169465A1 (en) 2002-01-09
DE69930147T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
CN103893747B (zh) 增强针对艾美球虫属的免疫反应的组合物和方法
CN111961138B (zh) 疫苗融合蛋白
KR20210092762A (ko) 아프리카 돼지 열병 바이러스에 대한 면역원성 조성물
JP2000503325A (ja) クラミジア感染に対するｄｎａ免疫法
Drew et al. Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the: Taenia ovis 45W antigen
JP2000516200A (ja) ウシの呼吸病に対するポリヌクレオチドワクチン処方
Shieh et al. Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization
RS60135B1 (sr) Vakcine protiv hlamidije sp.
JP3699421B2 (ja) アクチノバチルス・プレウロニウモニアからのタンパク質
Wang et al. Vaccination of mice with DNA vaccine induces the immune response and partial protection against T. spiralis infection
JP2013520487A (ja) 免疫原性タンパク質および組成物
US20250339506A1 (en) Compositions for use in treatment of chlamydia
US20090215151A1 (en) Two-Step Immunization Procedure Against Chlamydia Infection
JP4653934B2 (ja) バクテリオファージによって仲介される免疫化方法
JP3881514B2 (ja) クラミジア感染症に対するｄｎａ免疫化
US20240299528A1 (en) A dna plasmid sars-corona virus-2/covid-19 vaccine
Drew et al. Vaccination with plasmid DNA expressing antigen from genomic or cDNA gene forms induces equivalent humoral immune responses
CN113278634B (zh) 一种预防和治疗默克尔细胞癌的新型疫苗
Barfoed et al. Influence of routes and administration parameters on antibody response of pigs following DNA vaccination
JP4535874B2 (ja) 肝炎に対するバクテリオファージを介する免疫
US11000579B2 (en) Recombinant Eimeria maxima protein delivered as nanoparticles
Byeon et al. Generation of an attenuated Salmonella-delivery strains expressing adhesin and toxin antigens for progressive atrophic rhinitis, and evaluation of its immune responses in a murine model
KR20060128894A (ko) 클라미디아 감염에 대한 면역화
Han Development of a DNA vaccine against Streptococcus mutans: A novel approach to immunization against dental caries

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061204

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20061204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100728